IGC Pharma
4 hedge funds and large institutions have $12K invested in IGC Pharma in 2015 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
48% less capital invested
Capital invested by funds: $23K → $12K (-$11K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$11.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$3.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $7K | -$11.1K | -55,926 | -67% |
|
|
2
Citadel Advisors
Miami,
Florida
| $3K | -$3.61K | -18,195 | -59% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | +$1.19K | +5,968 | +144% |
|
IGC Hedge Fund Activity: Q4 2015 in Review
4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2015, worth a combined $12K — down 48% from $23K a quarter earlier.
Fund positioning in IGC was balanced in Q4 2015: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, adding an estimated $1.19K. The largest seller was Virtu KCG Holdings, cutting an estimated $11.1K.
- 4 institutional investors held IGC Pharma (IGC) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $12K of IGC Pharma stock for Q4 2015, down 48% quarter-over-quarter.
- 0 funds opened new IGC Pharma positions in Q4 2015 and 0 closed out.
- The largest IGC Pharma buyer in Q4 2015 was UBS Group, an estimated $1.19K added.
- The largest IGC Pharma seller in Q4 2015 was Virtu KCG Holdings, an estimated $11.1K sold.
Based on aggregated 13F filings for Q4 2015.